Stock INNO INNOCAN PHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : InnoCan Pharma Corporation

Financials InnoCan Pharma Corporation

Equities

INNO

CA45783P1027

Pharmaceuticals

Market Closed - Canadian Securities Exchange
Other stock markets
 03:59:09 2023-12-05 pm EST 		Intraday chart for InnoCan Pharma Corporation 5-day change 1st Jan Change
0.31 CAD -3.12% -24.39% +44.19%
Nov. 29 InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nov. 29 InnoCan Pharma Brief: Says "Surge" in revenue Primarily attributable to "Robust" sales performance of Subsidiary, B.I. Sky Global Ltd. MT

Valuation

Fiscal Period : December 2019 2020 2021 2022
Capitalization 1 17,7 49,1 157 39,6
Enterprise Value (EV) 1 15,8 46,8 146 34,7
P/E ratio -4,45x -4,28x -14,1x -10,5x
Yield - - - -
Capitalization / Revenue - 6 132 126 693x 802 166 588x 15 473 823x
EV / Revenue - 6 132 126 405x 802 166 532x 15 473 821x
EV / EBITDA -5 906 670x -10 471 080x -21 140 869x -6 354 920x
EV / FCF -18 300 682x 16 380 320x -21 223 270x -6 340 166x
FCF Yield 0,00% 0,00% 0,00% 0,00%
Price to Book 12,5x -13,7x 17,4x 6,19x
Nbr of stocks (in thousands) 143 866 186 523 248 490 249 728
Reference price 2 0,12 0,26 0,63 0,16
Announcement Date 04/08/20 03/31/21 03/31/22 03/30/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period : December 2018 2019 2020 2021 2022
Net sales - - 0,01 0,20 2,56
EBITDA - -3,00 -4,69 -7,44 -6,23
EBIT 1 -0,33 -3,00 -4,73 -7,48 -6,27
Operating Margin - - -59 063% -3 816% -245%
Earnings before Tax (EBT) 1 -0,33 -3,34 -9,95 -10,1 -3,89
Net income 1 -0,33 -3,34 -9,95 -10,0 -3,76
Net margin - - -124 413% -5 126% -147%
EPS 2 -0,17 -0,03 -0,06 -0,04 -0,02
Free Cash Flow - -0,97 2,99 -7,41 -6,25
FCF margin - - 37 436% -3 780% -244%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 05/31/19 04/08/20 03/31/21 03/31/22 03/30/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period : December 2018 2019 2020 2021 2022
Net Debt - - - - -
Net Cash position - 1,90 2,30 11,0 4,91
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - -0,97 2,99 -7,41 -6,25
ROE (net income / shareholders' equity) - -433% 907% -373% -51,1%
Shareholders' equity 1 - 0,77 -1,10 2,69 7,37
ROA (Net income/ Total Assets) - -116% -85,4% -55,3% -40,1%
Assets 1 - 2,88 11,7 18,2 9,40
Book Value Per Share 2 0,01 0,01 -0,02 0,04 0,03
Cash Flow per Share - 0,01 0,01 0,04 0,02
Capex - 0,01 - 0,04 0,03
Capex / Sales - - - 20,9% 1,02%
Announcement Date 05/31/19 04/08/20 03/31/21 03/31/22 03/30/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
INNOCAN PHARMA CORPORATION Stock InnoCan Pharma Corporation
+44.19% 63 M $
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+60.77% 527 B $
NOVO NORDISK A/S Stock Novo Nordisk A/S
+46.50% 448 B $
JOHNSON & JOHNSON Stock Johnson & Johnson
-10.25% 382 B $
MERCK & CO., INC. Stock Merck & Co., Inc.
-4.25% 266 B $
ABBVIE INC. Stock AbbVie Inc.
-10.54% 255 B $
ROCHE HOLDING AG Stock Roche Holding AG
-13.61% 227 B $
NOVARTIS AG Stock Novartis AG
+1.76% 203 B $
ASTRAZENECA PLC Stock AstraZeneca PLC
-9.57% 201 B $
PFIZER, INC. Stock Pfizer, Inc.
-43.23% 165 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock InnoCan Pharma Corporation - Canadian Securities Exchange
  4. Financials InnoCan Pharma Corporation
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer